Vanda is a cash-rich small-cap biotech trying to outrun a 2027 patent cliff—now armed with a newly approved first-in-40-years motion-sickness drug and multiple near-term FDA catalysts.
Overview
Vanda Pharmaceuticals (VNDA) is a Washington, D.C.-based commercial-stage biopharma at a pivotal transition point: legacy, cash-generating products face loss of exclusivity, while multiple late-stage and newly approved assets aim to re-accelerate growth.
The near-term narrative changed materially with the **Dec 30, 2025 FDA approval of NEREUS (tradipitant)** for prevention of vomiting due to motion sickness—described as the first novel pharmacologic mechanism in this indication in over four decades. This approval provides an immediate commercial catalyst and validates VNDA’s model of acquiring/repurposing overlooked compounds.
VNDA currently markets **Fanapt** (schizophrenia + Bipolar I), **Hetlioz** (Non-24 and SMS sleep disturbances), and **Ponvory** (relapsing MS; acquired late 2023). Q3 2025 net product sales were **$56.3M (+18% YoY)**, driven mainly by **Fanapt (+31% YoY)** after the Bipolar I expansion. Despite revenue growth, VNDA remains in an investment phase with elevated SG&A and R&D, producing a Q3 2025 net loss of **-$22.6M**.
A defining strength is the balance sheet: **$293.8M cash/securities and zero debt** (Sept 30, 2025), giving runway into 2028 and reducing near-term dilution risk. The next key catalyst is **Bysanti (milsaperidone)** with a **Feb 21, 2026 PDUFA**, plus a forced FDA re-review of **Hetlioz Jet Lag** (decision due Jan 7, 2026) and a submitted **imsidolimab BLA** for GPP. The core strategic question for investors is whether these assets can replace/extend revenue ahead of **Fanapt generic entry in Nov 2027**.